<?xml version="1.0"?>
<response>
<item key="0">
<title>IL-23 Inhibition Across Psoriatic Disease* and Inflammatory Bowel Disease†</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-12-17T09:00:00-05:00">Dec 17, 2025</time> ]]>
</created>
<body>
<![CDATA[ Watch Dr. Khattri & Jennifer Labas, MSN, discuss IL-23 inhibition in adults with active PsA, moderate to severe plaque PsO, moderately to severely active UC, & moderately to severely active CD ]]>
</body>
<field_media_image>https://rheumnow.com/sites/default/files/styles/876_494_new/public/2025-12/IL-23%20inhibition%20RheumNow%20video_front%20image%20for%20landing%20page_20Nov25%20%281%29.png?h=f71907df</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Johnson & Johnson</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>48181</nid>
</item>
<item key="1">
<title>Underserved and Under-treated</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-11-30T18:54:31-05:00">Nov 30, 2025</time> ]]>
</created>
<body>
<![CDATA[ Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Vaccine Pearls &amp; Health Maintenance in the Rheum Clinic, Lifestyle Medicine and Pain Management. ]]>
</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-12/Christine%20APP%20Rx%20Update%20Title%20Card.jpg?h=c71d0c67</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/25803" hreflang="en">Shannon Rushe</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">RheumNow</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>47989</nid>
</item>
<item key="2">
<title>Sjögren’s Disease – What Are You Missing?</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-11-01T09:00:00-04:00">Nov 01, 2025</time> ]]>
</created>
<body>What could you be missing in Sjögren's disease? Explore hypothetical patient cases with atypical presentations, systemic manifestations, and overlooked symptoms. Gain expert insights and practical tips for clinical assessment from Dr Shereen Mahmood and learn how the ESSDAI can help you measure disease activity.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-10/Dr%20Shereen%20Mahmood%20thumbnail.png?h=063a8962</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Novartis Pharmaceuticals Corporation </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>47622</nid>
</item>
<item key="3">
<title>A JAKi in GCA: Phase 3 Results Through 2 Years</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-11-01T09:00:00-04:00">Nov 01, 2025</time> ]]>
</created>
<body>Listen as rheumatologists Dr. Anisha Dua and Dr. Ben Boone discuss the latest efficacy and safety results over 2 years from a Phase 3 trial in GCA, including remission, flares, and glucocorticoid use in patients continuing vs withdrawing a JAKi"</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-10/RNTU12_Sidebar.png?h=8df7631e</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AbbVie Medical Affairs + Health Impact </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>47677</nid>
</item>
<item key="4">
<title>A JAKi CHAT: Shared Decision-Making in RA </title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-10-01T09:00:00-04:00">Oct 01, 2025</time> ]]>
</created>
<body>Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-10/AbbVie%20November%20.png?h=5cf3d0e0</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AbbVie Medical Affairs + Health Impact </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>46655</nid>
</item>
<item key="5">
<title>ILD Treatment and Guidelines</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-09-01T20:44:16-04:00">Sep 01, 2025</time> ]]>
</created>
<body>Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-10/Hinze%20Title%20Card%20ILD.jpg?h=c71d0c67</field_media_image>
<field_full_name/>
<field_author_attribution>
<![CDATA[ <span class="name" title="More by this author"> </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>46274</nid>
</item>
<item key="6">
<title>Structural damage progression in active PsA</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-09-01T08:00:00-04:00">Sep 01, 2025</time> ]]>
</created>
<body>Watch Dr. Philip Mease discuss the impact of structural damage on active PsA and follow along as he reviews clinical trial data</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-08/J%26J.jpg?h=8abcec71</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Johnson &amp; Johnson</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>46030</nid>
</item>
<item key="7">
<title>Navigating the Path to SLE Remission</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-08-01T06:00:00-04:00">Aug 01, 2025</time> ]]>
</created>
<body>Watch rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-08/RN%20%E2%80%93%20Thumbnail-16_9%202025%20%281%29.png?h=6e542444</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AstraZeneca Medical Affairs</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>46028</nid>
</item>
<item key="8">
<title>GCA: Case by Case</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-07-01T05:00:00-04:00">Jul 01, 2025</time> ]]>
</created>
<body>Dive into 4 hypothetical case studies that reveal the diverse and often complex presentations of giant cell arteritis (GCA). Each case is guided by expert commentary from Dr Michael Putman, where he offers practical insights and clinical pearls to enhance your therapeutic strategies for this multifaceted condition.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-07/NOV-11428621-rheumnowPostJuly_thumbnail%20%281%29.jpg?h=8abcec71</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Novartis US Medical Affairs</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>45781</nid>
</item>
<item key="9">
<title>Debunked. Expert perspectives on Sjögren’s Disease myths</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-06-01T05:15:00-04:00">Jun 01, 2025</time> ]]>
</created>
<body>How well do you know Sjögren’s disease? Test your knowledge and then hear rheumatologist, Dr Sara McCoy, discuss common myths and realities about managing patients with Sjögren’s disease.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-08/NOV-FA-11441522-rheumnowPostJune_thumbnail%20%282%29.jpg?h=44b879e5</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Novartis Medical Affairs </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>44949</nid>
</item>
<item key="10">
<title>Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-06-01T05:10:00-04:00">Jun 01, 2025</time> ]]>
</created>
<body>Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor's potential role in managing patients with PsA.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-06/Thumb-Post10%20%282%29.png?h=6e542444</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AbbVie Medical Affairs + Health Impact </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>44950</nid>
</item>
<item key="11">
<title>A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-05-01T05:00:00-04:00">May 01, 2025</time> ]]>
</created>
<body>Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-05/382%20x%20219.png?h=def129f6</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AbbVie Medical Affairs + Health Impact</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>44498</nid>
</item>
<item key="12">
<title>Lupus Nephritis</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-04-30T22:26:45-04:00">Apr 30, 2025</time> ]]>
</created>
<body>View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-05/Anders%20Rx%20Update%20Title%20Card%20CKD.jpg?h=c71d0c67</field_media_image>
<field_full_name/>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by RheumNow</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>44495</nid>
</item>
<item key="13">
<title>Biomarkers in RA</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-04-01T09:00:00-04:00">Apr 01, 2025</time> ]]>
</created>
<body>Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-04/Augrex%20RX%20Update%20Front%20End%20Image.jpg?h=093f500d</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Augurex </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>44170</nid>
</item>
<item key="14">
<title>Treatment goals for RA: Is it time to transition MOAs?</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-03-01T09:00:00-05:00">Mar 01, 2025</time> ]]>
</created>
<body>Rheumatologists Dr. Christina Charles-Schoeman and Dr. Manish Jain discuss their approaches to setting and pursuing treatment goals for patients with poorly controlled RA after TNFis</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-03/Thumb-Post8.png?h=abf9ee91</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AbbVie Medical Affairs + Health Impact</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>43880</nid>
</item>
<item key="15">
<title>EXXELERATE: New Thoughts on High RF Titer</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-03-01T07:00:00-05:00">Mar 01, 2025</time> ]]>
</created>
<body>Two leading rheumatologists share insights into why RF levels are important to consider when identifying treatment options for patients with RA.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-03/Template_title-image.png?h=f51ee74d</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by: UCB</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>43922</nid>
</item>
<item key="16">
<title>Autoimmune Myositis: The Role of the Laboratory in Diagnosis and Phenotyping</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2025-02-01T09:00:00-05:00">Feb 01, 2025</time> ]]>
</created>
<body>Hear from rheumatologist Stanley J. Naides MD, FACP, FACR, as he details the clinical features of autoimmune myositis, the associated phenotypes and autoantibodies, plus the methodologies and testing options to support a myositis diagnosis.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2025-02/1101252_EB_Autoimmune%20Myositis%20Podcast_v1_Low%20res_0.jpg?h=ae1281eb</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Labcorp</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>43615</nid>
</item>
<item key="17">
<title>Minimizing Steroids in Lupus</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2024-11-01T09:00:00-04:00">Nov 01, 2024</time> ]]>
</created>
<body>Minimizing steroid use in patients with SLE. Learn more about when, why, and how to taper steroids and listen to experts, Dr Michelle Petri and Dr Leanna Wise, discuss key data and their clinical perspectives on these topics.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2024-11/RheumNow_GC%20Thumbnail_Webpage%20%281%29_0.jpg?h=b1646d6a</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AstraZeneca Medical Affairs</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>41998</nid>
</item>
<item key="18">
<title>RA Risk Radar: Heart Disease, Infection, and Malignancy</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2024-10-01T09:00:00-04:00">Oct 01, 2024</time> ]]>
</created>
<body>Listen as rheumatologists Dr. Jeffery Curtis and Dr. Jon Giles review comorbidities that can occur as a consequence of uncontrolled, or under-controlled, inflammation in rheumatoid arthritis. In this conversation they share their clinical expertise on a range of topics, including risk assessment, risk management, and the importance of disease control. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2024-10/RA%20Risk%20Radar_Thumbnail.png?h=a7a0ed67</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by AbbVie Medical Affairs</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>41755</nid>
</item>
<item key="19">
<title>Physician Case Reports: Manifestations in Patients with Severe Active GPA/MPA</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2024-10-01T09:00:00-04:00">Oct 01, 2024</time> ]]>
</created>
<body>A review of two physician case reports. These cases are patients who presented with severe active manifestations of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2024-10/Opening%20image%20RheumNow%202024-09-30%20105133.png?h=1d2675bc</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Amgen </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>41756</nid>
</item>
<item key="20">
<title>Earlier treatment with biologics to reduce the risk of organ damage in systemic lupus erythematosus (SLE)</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2024-09-01T05:00:00-04:00">Sep 01, 2024</time> ]]>
</created>
<body>Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of the disease by targeting its underlying mechanisms.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2024-08/RheumNow%20Thumbnail_0824%404x%20%281%29.png?h=5e996b54</field_media_image>
<field_full_name/>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by GSK US Medical Affairs</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>41513</nid>
</item>
<item key="21">
<title>Diagnosis of PMR</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2023-10-01T08:00:00-04:00">Oct 01, 2023</time> ]]>
</created>
<body>Nine perspectives now available: Red Flags in the Diagnosis of PMR; Epidemiology of PMR; Role of the PCP in Diagnosis and Care; Importance of Diagnostic Imaging; ESR/CRP in PMR; PMR Must Rule Outs; Which PMR Patients Should Rheumatologists See?; Is There Hidden GCA?; and PMR Mimics. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2023-10/Yates%20Rx%20Update%20Title_0.png?h=d1cb525d</field_media_image>
<field_full_name/>
<field_author_attribution>
<![CDATA[ <span class="name">RheumNow</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>36662</nid>
</item>
<item key="22">
<title>Hard Decisions in RA</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2023-09-01T10:00:00-04:00">Sep 01, 2023</time> ]]>
</created>
<body>Eight debates and perspectives on Hard Decisions in RA now available.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2023-10/TU%20Weinblatt.png?h=d1cb525d</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21150" hreflang="en">Brandi Waits</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by RheumNow </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>36367</nid>
</item>
<item key="23">
<title>Women in Rheumatology: Gender Issues in Disease and Management</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2023-04-03T09:46:54-04:00">Apr 03, 2023</time> ]]>
</created>
<body>Nine videos discussing gender differences in axSpA, PsA, Vasculitis, Lung Disease, Osteoporosis, Disparities in Healthcare, and Rheumatologic Activity and Treatment, are now available. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2023-04/WIRTU%20Week4%20nologo.png?h=8abcec71</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/20781" hreflang="en">John Swope</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Bristol Myers Squibb</span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>34641</nid>
</item>
<item key="24">
<title>
<![CDATA[ Solving Still&#039;s Disease ]]>
</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2022-07-01T09:00:00-04:00">Jul 01, 2022</time> ]]>
</created>
<body>Dr. Jack Cush reviews the history, manifestations, diagnosis and treatment of Still's disease. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2022-07/Stills_TU-image.jpg</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21163" hreflang="en">RheumNow</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name" title="More by this author"><a href="/user/21163" hreflang="en">RheumNow</a> </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>30631</nid>
</item>
<item key="25">
<title>The Future of PsA</title>
<field_additional_authors/>
<field_rxu_is_sponsored>Off</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2022-04-01T09:00:01-04:00">Apr 01, 2022</time> ]]>
</created>
<body>As we conclude our PsA campaign, Dr. Ogdie shares information about Preventing PsA and Dr. Ritchlin discusses Future Discovery and Targets.</body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2022-04/Ogdie%20Ritchlin%20TU.png</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21163" hreflang="en">RheumNow</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name" title="More by this author"><a href="/user/21163" hreflang="en">RheumNow</a> </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>29051</nid>
</item>
<item key="26">
<title>Women Leaders in Rheumatology: Leadership in a Virtual World</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2021-12-01T09:00:00-05:00">Dec 01, 2021</time> ]]>
</created>
<body>A moderated panel of prominent female rheumatologists will discuss the challenges and successes in clinical practice and research that they encountered during the COVID-19 pandemic. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2021-12/WomenRheum_v2.png</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/20781" hreflang="en">John Swope</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name">Sponsored by Bristol Myers Squibb and the Bristol Myers Squibb Network of Women (B-NOW) </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>27826</nid>
</item>
<item key="27">
<title>COVID-19 Patient PSA Video Series </title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2020-03-30T10:33:06-04:00">Mar 30, 2020</time> ]]>
</created>
<body>Dr. Jack Cush provides a series of "Patient Safety Advisories" on how patients can cope with the COVID-19 pandemic and rheumatology-related illnesses. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2020-05/Rheumnow%2520PSA%2520Series%2520Title%2520Page_3.png</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21163" hreflang="en">RheumNow</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name" title="More by this author"><a href="/user/21163" hreflang="en">RheumNow</a> </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>13149</nid>
</item>
<item key="28">
<title>Biosimilars in Rheumatology</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2019-05-31T14:54:51-04:00">May 31, 2019</time> ]]>
</created>
<body>A first-of-its kind educational video series focusing on the “hot topics” in biosimilars from the perspective of leading Rheumatology experts. This educational series is presented by Sandoz, Inc. </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/2020-05/Sandoz%2520Matrix_0.png</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21163" hreflang="en">RheumNow</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name" title="More by this author"><a href="/user/21163" hreflang="en">RheumNow</a> </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>12658</nid>
</item>
<item key="29">
<title>Best of EULAR 2018</title>
<field_additional_authors/>
<field_rxu_is_sponsored>On</field_rxu_is_sponsored>
<created>
<![CDATA[ <time datetime="2018-06-22T11:50:16-04:00">Jun 22, 2018</time> ]]>
</created>
<body>A video matrix of the best moments and findings from our coverage of EULAR 2018 in Amsterdam </body>
<field_media_image>/sites/default/files/styles/rheumnow_featured_image_16_9/public/EULAR2018_Matrix.png</field_media_image>
<field_full_name>
<![CDATA[ <a href="/user/21163" hreflang="en">RheumNow</a> ]]>
</field_full_name>
<field_author_attribution>
<![CDATA[ <span class="name" title="More by this author"><a href="/user/21163" hreflang="en">RheumNow</a> </span> ]]>
</field_author_attribution>
<field_show_author>1</field_show_author>
<nid>12662</nid>
</item>
</response>